Migraine is ranked as a leading cause of years lived with disability among all neurological disorders. Therapies targeting the calcitonin gene-related peptide (CGRP) signaling pathway, including monoclonal antibodies against the receptor or ligand and small molecule CGRP receptor antagonists (gepants), are today approved for migraine prophylaxis with additional compounds expected to be introduced to the market soon. In this review, we consider other putative prophylactic migraine drugs in development, including compounds targeting G-protein coupled receptors, glutamate, ion channels, and neuromodulatory devices. Emergence of these new interventions could complement our current treatment armamentarium for migraine management.Le texte complet de cet article est disponible en PDF.
Keywords : Headache, CGRP, PACAP, Gepant, Ditan, Glutamate, Serotonin, Orexin, ASIC, TRP channel, Ion channel, Neurostimulation, Prevention, Preventive